July 21, 2017 10:14 AM EDT
Startups
Pharma

An up­start in the poly­clon­al an­ti­body biz just lined up $50M for its plan to dis­rupt a multi­bil­lion-dol­lar busi­ness

John Carroll

Editor & Founder

The multi­bil­lion-dol­lar busi­ness for im­muno­glo­bin prod­ucts is dom­i­nat­ed by three key play­ers: CSL, Shire and Gri­fols. And one of them re­cent­ly in­vest­ed $50 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times